Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells.

  • Veron Ramsuran ,
  • Vivek Naranbhai ,
  • Amir Horowitz ,
  • Ying Qi ,
  • Maureen P. Martin ,
  • Yuko Yuki ,
  • Xiaojiang Gao ,
  • Victoria Walker-Sperling ,
  • Gregory Q. Del Prete ,
  • Douglas K. Schneider ,
  • Jeffrey D. Lifson ,
  • Jacques Fellay ,
  • Steven G. Deeks ,
  • Jeffrey N. Martin ,
  • James J. Goedert ,
  • Steven M. Wolinsky ,
  • Nelson L. Michael ,
  • Gregory D. Kirk ,
  • Susan Buchbinder ,
  • David Haas ,
  • Thumbi Ndung’u ,
  • Philip Goulder ,
  • Peter Parham ,
  • Bruce D. Walker ,
  • ,
  • Mary Carrington

Science | , Vol 359: pp. 86-90

Publication

The highly polymorphic human leukocyte antigen (HLA) locus encodes cell surface proteins that are critical for immunity. HLA-A expression levels vary in an allele-dependent manner, diversifying allele-specific effects beyond peptide-binding preference. Analysis of 9763 HIV-infected individuals from 21 cohorts shows that higher HLA-A levels confer poorer control of HIV. Elevated HLA-A expression provides enhanced levels of an HLA-A-derived signal peptide that specifically binds and determines expression levels of HLA-E, the ligand for the inhibitory NKG2A natural killer (NK) cell receptor. HLA-B haplotypes that favor NKG2A-mediated NK cell licensing (i.e., education) exacerbate the deleterious effect of high HLA-A on HIV control, consistent with NKG2A-mediated inhibition impairing NK cell clearance of HIV-infected targets. Therapeutic blockade of HLA-E:NKG2A interaction may yield benefit in HIV disease.